Chitosan Outpaced Other Natural Agents in Late-Stage Rat Wound Repair
A rat excisional wound model found that chitosan, stem cells, Aloe vera, and hyaluronic acid all improved skin repair compared with untreated controls, but the trajectory was not identical across the healing window. The sharpest early gains appeared with stem cell treatment on days 3 and 7, while chitosan produced the strongest overall performance by day 14, including the highest tissue growth marker and immune marker values among the treated groups.
The pattern matters because wound healing is not a single event. It unfolds through inflammation, proliferation, tissue remodeling, and re-epithelialization, and an intervention can look strong in one phase while lagging in another. Here, the biologic behavior of each treatment seemed to map onto those phases rather than offering a uniform effect across all time points.
A Controlled Excision Model Built to Track Repair Over Time
Seventy healthy adult male Sprague–Dawley rats were assigned to five groups, with one group left untreated after wound induction and four groups receiving topical or cellular therapy. The animals underwent a circular dorsal excision wound created with a biopsy punch, then were followed for wound diameter change on the 3rd, 7th, and 14th days. Treatment arms included Aloe vera gel, a single injection of bone marrow-derived mesenchymal stem cells, a 2% water-soluble chitosan dressing, and 0.2% hyaluronic acid hydrogel.
The study design was straightforward but biologically ambitious. Each agent acts through a different repair pathway: Aloe vera is commonly linked to anti-inflammatory and regenerative effects; chitosan can support cell adhesion, growth factor signaling, and angiogenesis; hyaluronic acid contributes to cell migration and matrix organization; and stem cells can release paracrine signals that accelerate vascular and tissue repair. In a wound bed, those pathways can converge on the same visible endpoint while still producing different microscopic signatures.
Early Contraction Favored Stem Cells, but the Late Edge Shifted to Chitosan
Wound contraction measurements showed a clear phase-dependent separation between the treatment groups. Stem cells led on days 3 and 7, with chitosan close behind and no significant difference between them at those earlier checkpoints. By day 14, however, chitosan surpassed all other experimental groups in wound contraction.
That late divergence is clinically meaningful in mechanistic terms. Early wound closure often reflects rapid cellular signaling and improved local repair activity, while later closure depends on sustained matrix deposition, organized re-epithelialization, and a stable inflammatory reset. Chitosan appears to have supported the latter process especially well in this model, which may explain why it overtook the stem cell arm after the first week.
Untreated wounds did not share that trajectory. The control group lacked the same degree of contraction and tissue recovery, reinforcing the baseline burden of delayed healing when no active regenerative agent is applied.
Tissue Markers Pointed to Stronger Regenerative Signaling With Chitosan
Biochemical and immunohistochemical assessment supported the same general hierarchy. On day 14, both tissue growth markers and immune markers were highest in the chitosan-treated group, followed by the stem cell-treated group. The study measured VEGF, IGF-1, EGF, and immunostaining for TGF-β3 and VEGF, linking the observed wound closure to a molecular repair program rather than surface-level contraction alone.
That molecular profile fits wound biology. VEGF promotes angiogenesis, which supplies oxygen and nutrients to the healing bed. EGF and IGF-1 support cell proliferation and migration, while TGF-β family signaling helps coordinate extracellular matrix remodeling and tissue repair. When those markers rise together, the wound environment is shifting toward productive regeneration rather than lingering inflammation.
Histology Matched the Gross Healing Pattern
Microscopic examination at days 3, 7, and 14 added a structural readout to the numerical measurements. The treated groups showed improved healing, reflected in photomicrographs and pathological alteration charts that documented more favorable tissue regeneration than the untreated group. The report describes histopathological and immunohistochemical changes consistent with enhanced repair in the treated wounds, with the strongest late-stage recovery again aligning with chitosan.
This kind of tissue-level confirmation is important because a wound can appear smaller at the surface while still failing to rebuild normal architecture underneath. Histology helps separate superficial contraction from genuine repair. In this study, the microscopic findings supported a real regenerative response in the treatment groups rather than a cosmetic reduction in wound size alone.
What the Rat Model Can and Cannot Tell Clinicians
This experiment offers a useful comparison of four biologically active wound therapies, but it remains a rat model with a single wound type, a small number of animals per group, and no human outcomes. The study also did not provide clinical infection rates, pain scores, scar quality metrics, or long-term functional endpoints. Those gaps matter because the best-performing agent in a controlled animal model does not automatically become the best choice for human chronic wounds, diabetic ulcers, or contaminated injuries.
Even so, the directional signal is clear: all four interventions improved repair, and chitosan emerged as the strongest late-phase agent in this setting. Stem cells appeared to accelerate early healing, which suggests a faster initial biologic push, but the chitosan arm produced the most robust day-14 contraction and the highest marker expression linked to angiogenesis and tissue regeneration. For wound research, that split is more informative than a simple win-or-lose result. It suggests that repair can be optimized either by pushing early cellular activity or by sustaining the later remodeling phase, and this study points to chitosan as the more durable driver of that second phase in rats.